Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures

January 17, 2026 updated by: Ahmed Mohamed Hassan, Cairo University

Comparison Between the Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures: A Randomized Controlled Trial

This work aims to investigate the diuretic effect of Aminophylline in comparison to Furosemide in adult patients undergoing cardiac surgical procedures.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Acute Kidney injury (AKI) is a serious and common complication after either adult or pediatric cardiac surgery.

The results of a recent meta-analysis suggested that loop diuretics (furosemide) may reduce postoperative creatinine clearance, whereas aldosterone agonists (spironolactone) increase the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI). Diuretics are not recommended for the prevention of AKI, but loop diuretics may be used for the management of volume overload Aminophylline in cardiac surgery can reduce the frequency of AKI and could be used in the prevention of AKI as a safe and efficient modality in high-risk patients.

Study Type

Interventional

Enrollment (Estimated)

106

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Cairo, Egypt, 12613
        • Recruiting
        • Cairo University
        • Contact:
        • Sub-Investigator:
          • Maged Salah, MD
        • Sub-Investigator:
          • Pierre Zarif, MD
        • Sub-Investigator:
          • Maged Abdel Waha, MD
        • Sub-Investigator:
          • Sherif Mamdouh, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age from 18-65 years.
  • Both sexes.
  • All adult patients presenting for elective cardiac surgical procedures performed on cardiopulmonary bypass (Coronary artery bypass surgery, Cardiac valve repair and/or replacement, Repair of large septal defects, Repair and/or palliation of congenital heart defects, Transplantation, surgery of thoracic aneurysms.).
  • Body mass index (BMI) ranged between 20 and 40 kg/m2.

Exclusion Criteria:

  • Sensitivity or contraindication to Aminophylline or furosemide
  • Stage-5 chronic kidney disease (CKD) [Glomerular filtration rate (GFR) of less than 15 mL/min].
  • The presence of both factors (GFR less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease.
  • Recipients of dialysis before surgery.
  • Recipients of solid-organ transplantation before surgery.
  • Emergency cardiac surgical procedures (e.g. left main coronary artery bypass graft, stuck valves, etc).
  • Patient refusal.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Aminophylline group (control group)
Patients will receive Aminophylline.
Drug: Aminophylline
Patients will receive Aminophylline.
Experimental: Furosemide group
Patients will receive furosemide.
Drug: Furosemide
Patients will receive furosemide.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement of urine output
Time Frame: Two hours after cardiopulmonary bypass
Urine output will be measured at two hours after cardiopulmonary bypass.
Two hours after cardiopulmonary bypass

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measurement of urine output at completion of cardiopulmonary bypass
Time Frame: 48 hours after cardiopulmonary bypass
Urine output at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB.
48 hours after cardiopulmonary bypass
Urea level
Time Frame: 48 hours after cardiopulmonary bypass
Urea level will be measured at 8 hours and 48 hours after cardiopulmonary bypass.
48 hours after cardiopulmonary bypass
Creatinine level
Time Frame: 48 hours after cardiopulmonary bypass
Creatinine level will be measured at 8 hours and 48 hours after cardiopulmonary bypass.
48 hours after cardiopulmonary bypass
Lactate level
Time Frame: 48 hours after cardiopulmonary bypass
Lactate level will be measured at 8 hours and 48 hours after cardiopulmonary bypass.
48 hours after cardiopulmonary bypass
Estimated Glomerular Filtration Rate (eGFR)
Time Frame: 48 hours after cardiopulmonary bypass
Estimated Glomerular Filtration Rate (eGFR) at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB.
48 hours after cardiopulmonary bypass
Measurement of fluid balance
Time Frame: 48 hours after cardiopulmonary bypass
Fluid balance at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB.
48 hours after cardiopulmonary bypass

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 17, 2026

Primary Completion (Estimated)

July 26, 2026

Study Completion (Estimated)

July 26, 2026

Study Registration Dates

First Submitted

January 7, 2026

First Submitted That Met QC Criteria

January 15, 2026

First Posted (Actual)

January 16, 2026

Study Record Updates

Last Update Posted (Actual)

January 21, 2026

Last Update Submitted That Met QC Criteria

January 17, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MD-258-2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

IPD Sharing Time Frame

After the end of study for one year.

IPD Sharing Access Criteria

The data will be available upon a reasonable request from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Surgical Procedures

Clinical Trials on Aminophylline

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe